Tordoir J H M, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B, Herold U, Irwin E, Kroon A A, de Leeuw P, Peters T K, Kieval R, Cody R
Department of Surgery, University Hospital Maastricht, Maastricht, The Netherlands.
Eur J Vasc Endovasc Surg. 2007 Apr;33(4):414-21. doi: 10.1016/j.ejvs.2006.11.025. Epub 2007 Jan 16.
To assess perioperative outcomes and blood pressure (BP) responses to an implantable carotid sinus baroreflex activating system being investigated for the treatment of resistant hypertension.
We report on the first seventeen patients enrolled in a multicenter study. Bilateral perivascular carotid sinus electrodes (CSL) and a pulse generator (IPG) are permanently implanted. Optimal placement of the CSL is determined by intraoperative BP responses to test activations. Acute BP responses were tested postoperatively and during the first four months of follow-up.
Prior to implant, BP was 189.6+/-27.5/110.7+/-15.3 mmHg despite stable therapy (5.2+/-1.8 antihypertensive drugs). The mean procedure time was 202+/-43 minutes. No perioperative strokes or deaths occurred. System tests performed 1 or up to 3 days postoperatively resulted in significant (all p < or = 0.0001) mean maximum reduction, with standard deviations and 95% confidence limits for systolic BP, diastolic BP and heart rate of 28+/-22 (17, 39) mmHg, 16+/-11 (10, 22) mmHg and 8+/-4 (6, 11) BPM, respectively. Repeated testing during 3 months of therapeutic electrical activation demonstrated a durable response.
These preliminary data suggest an acceptable safety of the procedure with a low rate of adverse events and support further clinical development of baroreflex activation as a new concept to treat resistant hypertension.
评估正在研究用于治疗顽固性高血压的植入式颈动脉窦压力反射激活系统的围手术期结果和血压(BP)反应。
我们报告了多中心研究中入组的首批17例患者。双侧血管周围颈动脉窦电极(CSL)和脉冲发生器(IPG)被永久植入。CSL的最佳放置通过术中对测试激活的血压反应来确定。术后及随访的前四个月测试急性血压反应。
植入前,尽管进行了稳定治疗(5.2±1.8种抗高血压药物),血压仍为189.6±27.5/110.7±15.3 mmHg。平均手术时间为202±43分钟。未发生围手术期卒中或死亡。术后1天或长达3天进行的系统测试导致平均最大降幅显著(所有p≤0.0001),收缩压、舒张压和心率的标准差及95%置信区间分别为28±22(17, 39)mmHg、16±11(10, 22)mmHg和8±4(6, 11)次/分钟。在3个月的治疗性电激活期间重复测试显示出持久反应。
这些初步数据表明该手术安全性可接受,不良事件发生率低,并支持压力反射激活作为治疗顽固性高血压的新概念进一步开展临床研究。